select trial semaglutide cardiovascular outcomes without diabetes 2023 A Skeptical Take of Semaglutide for Cardiac Protection

Cardiovascular outcomes of semaglutide and tirzepatide for patients with type 2 diabetes in clinical practice

27.16

★★★★☆4.8 (126)

In patients with cardiovascular disease and overweight or obesity but no diabetes, semaglutide was superior to placebo in lowering the risk of major adverse cardiovascular events at a mean follow-up of 39.8

29.00

★★★★★4.9 (98)

Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes: The SELECT Trial

27.16

★★★★★5.0 (157)

❤️ Heart protection that works even without diabetes. The SELECT trial proved semaglutide 2.4 mg cut major cardiovascular events by 20% in people who had heart disease + overweight/obesity but no diabetes

26.47

★★★★★4.7 (84)

Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial

20.27

★★★★★4.9 (203)

💡SELECT Trial💡 A breakthrough in Cardiology Field SELECT trial published its findings on 11th November 2023. It showed a significant reduction in the incidence of CV death, nonfatal MI or…

29.95

★★★★★5.0 (176)

SELECT Cardiovascular Trial Information

20.18

★★★★★4.8 (132)